杜瓦卢马布
医学
封锁
胶质母细胞瘤
肿瘤科
内科学
免疫系统
免疫学
免疫疗法
癌症研究
无容量
受体
作者
Lakshmi Nayak,Nathan E. Standifer,Jörg Dietrich,Jennifer Leigh Clarke,Gavin P. Dunn,Michael K. Lim,Timothy Francis Cloughesy,Hui Kong Gan,Elizabeth Flagg,Elizabeth George,Sarah C. Gaffey,Julia Hayden,Christina Holcroft,Patrick Yung Wen,Mary J. Macri,Andrew J. Park,Toni Ricciardi,Aileen Ryan,Paul Otto Schwarzenberger,Ralph Rudolph Venhaus
标识
DOI:10.1158/1078-0432.ccr-21-4064
摘要
PURPOSE: PD-L1 is upregulated in glioblastoma and supports immunosuppression. We evaluated PD-L1 blockade with durvalumab among glioblastoma cohorts and investigated potential biomarkers. PATIENTS AND METHODS: MGMT unmethylated newly diagnosed patients received radiotherapy plus durvalumab (cohort A; n = 40). Bevacizumab-naïve, recurrent patients received durvalumab alone (cohort B; n = 31) or in combination with standard bevacizumab (cohort B2; n = 33) or low-dose bevacizumab (cohort B3; n = 33). Bevacizumab-refractory patients received durvalumab plus bevacizumab (cohort C; n = 22). Primary endpoints were: OS-12 (A), PFS-6 (B, B2, B3), and OS-6 (C). Exploratory biomarkers included: a systematic, quantitative, and phenotypic evaluation of circulating immune cells; tumor mutational burden (TMB); and tumor immune activation signature (IAS). RESULTS: No cohort achieved the primary efficacy endpoint. Outcome was comparable among recurrent, bevacizumab-naïve cohorts. No unexpected toxicities were observed. A widespread reduction of effector immune cell subsets was noted among recurrent patients compared with newly diagnosed patients that was partially due to dexamethasone use. A trend of increased CD8+Ki67+ T cells at day 15 was noted among patients who achieved the primary endpoint and were not on dexamethasone. Neither TMB nor IAS predicted outcome. CONCLUSIONS: Patients with recurrent glioblastoma have markedly lower baseline levels of multiple circulating immune cell subsets compared with newly diagnosed patients. An early increase in systemic Ki67+CD8+ cells may warrant further evaluation as a potential biomarker of therapeutic benefit among patients with glioblastoma undergoing checkpoint therapy. Dexamethasone decreased immune cell subsets. PD-L1 blockade and combination with standard or reduced dose bevacizumab was ineffective.
科研通智能强力驱动
Strongly Powered by AbleSci AI